Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

ClinicalTrials.gov ID: NCT03355209

Public ClinicalTrials.gov record NCT03355209. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Two-Part Study of ZX008 in Children and Adults With Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults With LGS, Followed by Part 2: An Open-label Extension to Assess Long-Term Safety of ZX008 in Children and Adults With LGS

Study identification

NCT ID
NCT03355209
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Enrollment
296 participants

Conditions and interventions

Interventions

  • ZX008 0.2 or 0.8 mg/kg/day Drug
  • Matching Placebo Drug

Drug

Eligibility (public fields only)

Age range
2 Years to 35 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 26, 2017
Primary completion
May 22, 2024
Completion
May 22, 2024
Last update posted
Jul 2, 2025

2017 – 2024

United States locations

U.S. sites
30
U.S. states
19
U.S. cities
29
Facility City State ZIP Site status
Ep0214 107 Tucson Arizona 85718
Ep0214 144 Los Angeles California 90095-1752
Ep0214 101 San Francisco California 94158
Ep0214 103 Aurora Colorado 80045
Ep0214 149 Washington D.C. District of Columbia 20010
Ep0214 115 Gulf Breeze Florida 32561
Ep0214 104 Miami Florida 33155
Ep0214 141 Orlando Florida 32803
Ep0214 121 Orlando Florida 32819
Ep0214 117 Atlanta Georgia 30328
Ep0214 110 Chicago Illinois 60611
Ep0214 140 Bethesda Maryland 20817
Ep0214 112 Boston Massachusetts 02114
Ep0214 136 Grand Rapids Michigan 49503
Ep0214 147 Royal Oak Michigan 48073
Ep0214 109 Rochester Minnesota 55905
Ep0214 132 Saint Paul Minnesota 55102
Ep0214 105 Hackensack New Jersey 07601
Ep0214 118 Livingston New Jersey 07039
Ep0214 150 Hartsdale New York 10530
Ep0214 142 New York New York 10016
Ep0214 131 Cleveland Ohio 44106
Ep0214 143 Portland Oregon 97239
Ep0214 120 Philadelphia Pennsylvania 19104-4318
Ep0214 139 York Pennsylvania 17403
Ep0214 146 Dallas Texas 75235
Ep0214 126 Fort Worth Texas 76104
Ep0214 145 San Antonio Texas 78207-3108
Ep0214 106 Salt Lake City Utah 84113
Ep0214 125 Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03355209, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 2, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03355209 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →